Search
zerlasiran
Indications:
- a long-acting agent directed at lowering Lp(a) levels*
* 90% reduction in serum Lp(a) levels in phase 2 trial
General
short interfering double-stranded RNA; antisense oligonucleotide (siRNA, microRNA, miRNA)
References
Hughes S
Phase 2 Results: Zerlasiran siRNA Drug Lowers Lp(a) by 90%
Cardiology News. March 18, 2024
https://www.mdedge.com/cardiology/article/268324/lipid-disorders/phase-2-results-zerlasiran-sirna-drug-lowers-lpa-90
https://www.medscape.com/viewarticle/zerlasiran-sirna-drug-lowers-lp-90-phase-2-results-2024a10004s8